Follow
Aaron Foster
Aaron Foster
Bellicum Pharmaceuticals, Inc.
Verified email at bellicum.com
Title
Cited by
Cited by
Year
A distinct “side population” of cells with high drug efflux capacity in human tumor cells
C Hirschmann-Jax, AE Foster, GG Wulf, JG Nuchtern, TW Jax, U Gobel, ...
Proceedings of the National Academy of Sciences 101 (39), 14228-14233, 2004
16982004
In vivo biodistribution of nanoparticles
JPM Almeida, AL Chen, A Foster, R Drezek
Nanomedicine 6 (5), 815-835, 2011
6012011
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model
A Di Stasi, B De Angelis, CM Rooney, L Zhang, A Mahendravada, ...
Blood, The Journal of the American Society of Hematology 113 (25), 6392-6402, 2009
5752009
Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b
JA Craddock, AN Lu, A Bear, M Pule, MK Brenner, CM Rooney, AE Foster
Journal of immunotherapy 33 (8), 780-788, 2010
5542010
Sox9 and NFIA coordinate a transcriptional regulatory cascade during the initiation of gliogenesis
P Kang, HK Lee, SM Glasgow, M Finley, T Donti, ZB Gaber, BH Graham, ...
Neuron 74 (1), 79-94, 2012
3472012
Improving T cell therapy for cancer
AM Leen, CM Rooney, AE Foster
Annu. Rev. Immunol. 25, 243-265, 2007
3112007
Epstein Barr virus–specific cytotoxic T lymphocytes expressing the anti-CD30ζ artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease
B Savoldo, CM Rooney, A Di Stasi, H Abken, A Hombach, AE Foster, ...
Blood, The Journal of the American Society of Hematology 110 (7), 2620-2630, 2007
2882007
Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-β receptor
AE Foster, G Dotti, A Lu, M Khalil, MK Brenner, HE Heslop, CM Rooney, ...
Journal of immunotherapy 31 (5), 500-505, 2008
2492008
Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and …
AA Kennedy-Nasser, S Ku, P Castillo-Caro, Y Hazrat, MF Wu, H Liu, ...
Clinical Cancer Research 20 (8), 2215-2225, 2014
2202014
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes
C Quintarelli, JF Vera, B Savoldo, GMP Giordano Attianese, M Pule, ...
Blood, The Journal of the American Society of Hematology 110 (8), 2793-2802, 2007
2042007
Gold nanoparticle delivery of modified CpG stimulates macrophages and inhibits tumor growth for enhanced immunotherapy
AY Lin, JP Mattos Almeida, A Bear, N Liu, L Luo, AE Foster, RA Drezek
PloS one 8 (5), e63550, 2013
1692013
Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation
K Micklethwaite, A Hansen, A Foster, E Snape, V Antonenas, M Sartor, ...
Biology of Blood and Marrow Transplantation 13 (6), 707-714, 2007
1652007
In vivo gold nanoparticle delivery of peptide vaccine induces anti‐tumor immune response in prophylactic and therapeutic tumor models
JPM Almeida, AY Lin, ER Figueroa, AE Foster, RA Drezek
Small 11 (12), 1453-1459, 2015
1632015
Elimination of metastatic melanoma using gold nanoshell-enabled photothermal therapy and adoptive T cell transfer
AS Bear, LC Kennedy, JK Young, SK Perna, JP Mattos Almeida, AY Lin, ...
PloS one 8 (7), e69073, 2013
1502013
A distinct “side population” of cells in human tumor cells: implications for tumor biology and therapy
C Hirschmann-Jax, AE Foster, GG Wulf, MA Goodell, MK Brenner
Cell Cycle 4 (2), 206-208, 2005
1422005
Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes
Y Nakazawa, LE Huye, G Dotti, AE Foster, JF Vera, PR Manuri, CH June, ...
Journal of immunotherapy 32 (8), 826-836, 2009
1312009
T cells enhance gold nanoparticle delivery to tumors in vivo
LC Kennedy, AS Bear, JK Young, NA Lewinski, J Kim, AE Foster, ...
Nanoscale research letters 6, 1-11, 2011
1252011
Human CD62L–memory T cells are less responsive to alloantigen stimulation than CD62L+ naive T cells: potential for adoptive immunotherapy and allodepletion
AE Foster, M Marangolo, MM Sartor, SI Alexander, M Hu, KF Bradstock, ...
Blood 104 (8), 2403-2409, 2004
1192004
Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7
JF Vera, V Hoyos, B Savoldo, C Quintarelli, GMPG Attianese, AM Leen, ...
Molecular Therapy 17 (5), 880-888, 2009
1062009
Optimization of PAMAM-gold nanoparticle conjugation for gene therapy
ER Figueroa, AY Lin, J Yan, L Luo, AE Foster, RA Drezek
Biomaterials 35 (5), 1725-1734, 2014
962014
The system can't perform the operation now. Try again later.
Articles 1–20